Visão geral da empresa
A biopharmaceutical entity, Scholar Rock Holding Corporation is dedicated to developing therapies that improve the lives of children and adults suffering from spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company operates within the Healthcare sector, specifically the Biotechnology industry, which is characterized by high-risk research and development phases aiming to bring novel treatments to market. Scholar Rock Holding Corporation currently holds a market capitalization of $5.74 billion and employs a workforce of 289 individuals to execute its mission. The substantial market cap of $5.74 billion, contrasted with the absence of reported annual revenue figures in the available data, indicates a company that is likely in a capital-intensive growth phase where valuation is driven by intellectual property and pipeline potential rather than current earnings generation.
Saúde financeira
The financial statements for Scholar Rock Holding Corporation show a Net Income of $-377,939,008 and an EBITDA of $-382,987,008 for the trailing twelve months, while Revenue figures are not available in the current dataset. The significant gap between the reported Net Income and EBITDA, which are nearly identical in magnitude, suggests that interest, taxes, and other non-operating expenses are minimal relative to the massive operating losses, highlighting a cost structure dominated by research and development expenditures. Free Cash Flow stands at $-162,622,256, indicating that the company is burning cash rapidly, which limits its immediate financial flexibility and reliance on external capital sources for operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported as 0.0%, which typically signifies that the company has not yet reached commercial profitability or that revenue data is insufficient to calculate meaningful margins in the current reporting period. The company maintains a Cash balance of $367.56M against total Debt of $108.92M, resulting in a Debt to Equity ratio of 44.37, which reflects a balance sheet that is leveraged but maintains a significant cash buffer relative to its obligations. The Current Ratio is 6.95, a figure that indicates strong short-term liquidity and an ability to cover current liabilities with current assets many times over. Return on Equity is -123.1% and Return on Assets is -54.7%, metrics that reveal that management is currently generating negative returns on both shareholder capital and the asset base, consistent with the pre-revenue or early-revenue stage of biotechnology development.
Avaliação de valorização
The Trailing Twelve Months P/E Ratio is listed as N/A, while the Forward P/E is -23.30, a disparity that implies the market is pricing in future earnings expectations that have not yet materialized in the current financial results. The Price to Book ratio is 22.09, indicating that the market values the company at a significant premium over its book value, a common phenomenon in biotechnology firms where intangible assets and pipeline value are not fully reflected on the balance sheet. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-14.32) suggest that traditional multiples are not applicable, with the negative EV/EBITDA reinforcing the company's loss-making status relative to its enterprise value. The stock's 52-Week High is $51.62 and the 52-Week Low is $22.71, providing a trading range within which the current price must be situated to assess relative strength or weakness against historical volatility. The Beta is 0.69, which indicates that the stock price tends to be less volatile than the broader market, moving with a lower amplitude of price fluctuation compared to the S&P 500 index.
Growth & Income
Revenue Growth and Earnings Growth rates are both listed as N/A, meaning there is no historical data available to determine if earnings are growing faster or slower than revenue within the current reporting framework. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that the organization reinvests all available earnings and cash reserves back into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of dividend income and reported growth rates, reflecting a strategic focus on capital appreciation through potential future product approvals rather than current yield generation.